scholarly journals Serum Unsaturated Free Fatty Acids: A Potential Biomarker Panel for Differentiating Benign Thyroid Diseases from Thyroid Cancer

2015 ◽  
Vol 6 (12) ◽  
pp. 1276-1281 ◽  
Author(s):  
Yaping Zhang ◽  
Ling Qiu ◽  
Chengyan He ◽  
Yanmin Wang ◽  
Yujie liu ◽  
...  
2016 ◽  
Vol 7 (4) ◽  
pp. 477-483 ◽  
Author(s):  
Yaping Zhang ◽  
Chengyan He ◽  
Ling Qiu ◽  
Yanmin Wang ◽  
Xuzhen Qin ◽  
...  

Biomarkers ◽  
2014 ◽  
Vol 19 (8) ◽  
pp. 667-673 ◽  
Author(s):  
Yaping Zhang ◽  
Ling Qiu ◽  
Yanmin Wang ◽  
Chengyan He ◽  
Xuzhen Qin ◽  
...  

Nutrients ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 742
Author(s):  
Simone Baldi ◽  
Marta Menicatti ◽  
Giulia Nannini ◽  
Elena Niccolai ◽  
Edda Russo ◽  
...  

Altered circulating levels of free fatty acids (FFAs), namely short chain fatty acids (SCFAs), medium chain fatty acids (MCFAs), and long chain fatty acids (LCFAs), are associated with metabolic, gastrointestinal, and malignant diseases. Hence, we compared the serum FFA profile of patients with celiac disease (CD), adenomatous polyposis (AP), and colorectal cancer (CRC) to healthy controls (HC). We enrolled 44 patients (19 CRC, 9 AP, 16 CD) and 16 HC. We performed a quantitative FFA evaluation with the gas chromatography–mass spectrometry method (GC–MS), and we performed Dirichlet-multinomial regression in order to highlight disease-specific FFA signature. HC showed a different composition of FFAs than CRC, AP, and CD patients. Furthermore, the partial least squares discriminant analysis (PLS-DA) confirmed perfect overlap between the CRC and AP patients and separation of HC from the diseased groups. The Dirichlet-multinomial regression identified only strong positive association between CD and butyric acid. Moreover, CD patients showed significant interactions with age, BMI, and gender. In addition, among patients with the same age and BMI, being male compared to being female implies a decrease of the CD effect on the (log) prevalence of butyric acid in FFA composition. Our data support GC–MS as a suitable method for the concurrent analysis of circulating SCFAs, MCFAs, and LCFAs in different gastrointestinal diseases. Furthermore, and notably, we suggest for the first time that butyric acid could represent a potential biomarker for CD screening.


2018 ◽  
Vol 103 (6) ◽  
pp. 2216-2224 ◽  
Author(s):  
Cari M Kitahara ◽  
Dóra Kӧrmendiné Farkas ◽  
Jens Otto L Jørgensen ◽  
Deirdre Cronin-Fenton ◽  
Henrik Toft Sørensen

2012 ◽  
Vol 23 (5) ◽  
pp. 745-755 ◽  
Author(s):  
Christophe Leux ◽  
Thérèse Truong ◽  
Claire Petit ◽  
Dominique Baron-Dubourdieu ◽  
Pascal Guénel

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Zhigang Hu ◽  
Pengxin Zhao ◽  
Kaili Zhang ◽  
Leilei Zang ◽  
Haiying Liao ◽  
...  

Vascular adhesion protein-1 (VAP-1) is a glycoprotein that mediates tissue-selective lymphocyte adhesion. The prognostic value of VAP-1 has been determined in gastric cancer. The aim of this study was to evaluate the changes and the predictive value of serum VAP-1 in patients with thyroid cancer. A total of 126 patients with thyroid nodules and 53 healthy controls participated in this study. The patients were further divided into subgroup 1 (69 cases with benign thyroid nodules) and subgroup 2 (57 cases with thyroid cancer). Serum VAP-1 was measured by time-resolved immunofluorometric assay. Diagnostic value of presurgical VAP-1 for thyroid cancer was conducted by receiver operating characteristic (ROC) curves. Serum levels of VAP-1 were significantly lower in thyroid cancer group than in healthy control and benign thyroid nodule groups. VAP-1 concentrations negatively correlated with serum thyroglobulin (Tg) levels in thyroid cancer patients (r=-0.81;p<0.001). The optimum cut-off value of VAP-1 was 456.6 ng/mL with a 77.4% specificity and 66.7% sensitivity for thyroid cancer diagnosis. Serum VAP-1 decreased in thyroid cancer patients and VAP-1 could be a potential useful adjunct biomarker in the diagnosis of thyroid cancer.


2012 ◽  
Vol 19 (5) ◽  
pp. 645-655 ◽  
Author(s):  
Trinh Trung Hieu ◽  
Anthony W Russell ◽  
Ross Cuneo ◽  
Justin Clark ◽  
Tomas Kron ◽  
...  

Radioiodine-131 (131I) is widely used for diagnosis and treatment of benign thyroid diseases. Observational studies have not been conclusive about the carcinogenic potential of131I and we therefore conducted a meta-analysis. We performed a literature search till September 2011 which included131I as a diagnostic or treatment modality (131I for treatment of thyroid cancer was excluded). Data on 64 different organ or organ group subsets comprising 22 029 exposed subjects in the therapeutic cohorts and 24 799 in the diagnostic cohorts in seven studies were included. Outcome was pooled as the relative risk (RR) using both standard and bias adjusted methods. Quality assessment was performed using a study-specific instrument. No increase in overall (RR 1.06, 95% CI: 0.94–1.19), main organ group or combined organ group (four groups known to concentrate131I; RR 1.11, 95% CI: 0.94–1.31) risks was demonstrable. Individual organs demonstrated a higher risk for kidney (RR 1.70, 95% CI: 1.15–2.51) and thyroid (RR 1.99, 95% CI: 1.22–3.26) cancers with a strong trend for stomach cancer (RR 1.11, 95% CI: 0.92–1.33). A thyroid dose effect was seen for diagnostic doses. While there is no increase in the overall burden of cancer, an increase in risk to a few organs is seen which requires substantiation. The possible increase in thyroid cancer risk following diagnostic131I use should no longer be of concern given that it has effectively been replaced by the use of 99mTc-pertechnetate.


Sign in / Sign up

Export Citation Format

Share Document